Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Elenestinib |
Synonyms | |
Therapy Description |
Elenestinib (BLU-263) inhibits KIT D816V, which potentially leads to decreased cell proliferation (Blood (2022) 140 (Supplement 1): 6877–6878; NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Elenestinib | BLU-263|BLU 263|BLU263 | KIT Inhibitor 57 | Elenestinib (BLU-263) inhibits KIT D816V, which potentially leads to decreased cell proliferation (Blood (2022) 140 (Supplement 1): 6877–6878; NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05609942 | Phase Ib/II | Elenestinib Azacitidine + Elenestinib | Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies (AZURE) | Recruiting | USA | NOR | NLD | FRA | ESP | DEU | BEL | 0 |
NCT04910685 | Phase II | Elenestinib | (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis | Recruiting | USA | NOR | NLD | ITA | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS | 1 |